Novo Nordisk’s Generics Defence in India Offers Blueprint as Amazon Widens US GLP-1 Access

Novo Nordisk's Ozempic and Wegovy sales rose 40% in India after patent expiry, as generics expand the market. New US deal with Amazon and promising clinical data add to bullish signals.

The first real-world test of Novo Nordisk’s ability to hold its ground against generic competition is delivering a surprisingly upbeat readout. In India, where the patent on semaglutide expired on March 20, the Danish drugmaker’s diabetes and weight-loss brands actually gained momentum rather than ceding share. Sales volumes of Ozempic and Wegovy surged 40 per cent in April to 32,000 units, according to market researcher Pharmarack, marking the first full month of generic availability.

Novo pre-empted the wave of copycat products from domestic giants Sun Pharma, Dr. Reddy’s, Zydus Lifesciences and Glenmark by slashing prices on starter doses by 36 to 48 per cent from April 1. The entry-level therapy now costs roughly $60 a month. Crucially, the overall market expanded 56 per cent to 414,000 units, suggesting generics are pulling in new patients rather than merely cannibalising branded sales. “Generics have so far expanded the market, not eroded the originator’s share significantly,” said Sheetal Sapale, a manager at Pharmarack.

The India experience carries weight well beyond the subcontinent. Semaglutide is the active ingredient behind Ozempic and Wegovy, two of Novo’s most critical growth engines. If the company can preserve pricing power and prescriber loyalty in a market where cheap alternatives are already on shelves, the argument improves for later patent cliffs in Canada, China and elsewhere. The US — Novo’s largest profit pool — remains shielded for now: the core patent runs to March 2026, with extensions pushing protection to December 2031. Canada has approved generics but has yet to launch commercially, while generic Ozempic in China is unlikely until next year despite expired patents.

While India tests brand resilience on price, the US is testing a different kind of access. Amazon Pharmacy has added the oral version of Ozempic to its same-day delivery network and selected kiosks at One Medical locations. Unlike the injectable, the tablet requires no refrigeration, making it easier to stock in automated kiosks. The price for self-pay patients is $149 a month, dropping to $25 with insurance. Amazon already carries Wegovy and Eli Lilly’s Foundayo, turning its platform into a direct comparator for the GLP-1 market. For Novo, the deal provides a new digital and physical distribution channel, but it also places its products alongside rivals, sharpening the focus on price, insurance coverage and therapy adherence. Amazon frames the move as closing a “critical access gap” for more than 36 million Americans with diabetes.

All of this lands in a week when investors are also parsing fresh clinical data. At the European Congress on Obesity in Istanbul (May 12–15), Novo is presenting 52 abstracts spanning Wegovy, higher-dose formulations, the oral tablet and the combination therapy CagriSema. The headline dataset comes from the STEP-UP study of a 7.2 mg semaglutide dose, where Wegovy HD delivered a mean weight loss of 20.7 per cent. Market attention is shifting beyond pure weight reduction toward cardiovascular health, physical function and patient subgroup outcomes. Also on the agenda is the OASIS-4 study of an oral Wegovy tablet, with an indirect comparison of oral semaglutide versus Orforglipron scheduled for Friday.

The share price reflects both the recent rebound and the lingering damage. Novo’s stock changed hands at 40.24 euros on Monday in Copenhagen, up 25.47 per cent over the past month but still down 9.93 per cent year-to-date and 33.95 per cent over twelve months. The gap to the 52-week high remains a chunky 42.61 per cent. Management has helped the mood by slightly improving its 2026 guidance: the expected currency-adjusted decline in sales and operating profit now sits between 4 and 12 per cent, versus a prior band of 5 to 13 per cent. Underpinning that revision is robust US adoption of the oral Wegovy tablet — prescriptions topped 200,000 in the week to April 17, with cumulative volumes exceeding two million since launch. CEO Mike Doustdar has pointed to double-digit growth for the tablet and a 65 per cent share of new Wegovy prescriptions for the brand.

India and Istanbul offer two different kinds of reassurance. The first shows that brand equity and local partnerships — Novo distributes Wegovy via Emcure Pharma (as Poviztra) and Ozempic via Abbott India (as Extensior) — can still generate volume even when cheaper copies appear. The second should, if the data deliver, reinforce confidence in the oral and high-dose pipelines that the market is betting on for the medium term. The risk is that weaker signals from Istanbul would leave the stock relying on distribution gains from Amazon and India alone — and with competition sitting on the same digital shelf, that is a narrower foundation than many investors would like.